1. Psoriasis
  2. Secukinumab Efficacy Examined Following Psoriasis

Secukinumab Efficacy Examined Following Psoriasis Relapse After Treatment Pause – Monthly Prescribing Reference (registration)

Posted on by

CNA Finance (press release)
Secukinumab Efficacy Examined Following Psoriasis Relapse After Treatment Pause
Monthly Prescribing Reference (registration)
Patients with moderate to severe plaque psoriasis rapidly regained clear or almost clear skin, as adjudged by the Psoriasis Area Severity Index, after treatment with secukinumab (Cosentyx; Novartis) following relapse during a treatment pause. The new ...
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pauseYahoo Finance
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pauseP&T Community
Novartis' Cosentyx effective in clearing skin in psoriasis patients following relapseSeeking Alpha
EconoTimes -CNA Finance (press release)
all 7 news articles »

Here is the original post:

Secukinumab Efficacy Examined Following Psoriasis Relapse After Treatment Pause - Monthly Prescribing Reference (registration)

Related Posts

Comments are closed.


  1. Psoriasis
  2. Secukinumab Efficacy Examined Following Psoriasis